The Med Map

Your Roadmap to Better Prices

Patients save $500–$3,000/year — often much more on brand-name cardiac drugs.*

1Check First (5 min)

  • → Manufacturer copay card (if commercially insured)
  • → Cost Plus Drugs (if generic available)
  • → Walmart $4 list (if generic available)

2Deeper Savings (15 min)

  • → PharmacyChecker international (70–94% savings)
  • → 1800RxOnline.com
  • → GoodRx + SingleCare comparison

3If Still Too Expensive

  • → NeedyMeds / RxAssist PAP application
  • → Medicare Extra Help (if on Medicare)
  • → BenefitsCheckUp for state programs

What medication are you looking for?

Enter the name of the drug you need — brand name or generic.

Optional — leave blank to see general options

Stay Informed

Get notified when drug prices change

We monitor manufacturer savings cards, TrumpRx additions, and major price changes so you don't have to. Plus: open enrollment reminders and a January deductible-reset alert.

No spam, just value. Unsubscribe anytime.

Browse All Options

All 8 categories of savings options — expand any section to see sources and direct links.

Important: Copay Cards Don't Work for Medicare/Medicaid

Manufacturer copay cards (Eliquis, Xarelto, Entresto, Jardiance, Farxiga, Brilinta, and others) are only available to patients with commercial insurance. Medicare and Medicaid patients should focus on Patient Assistance Programs, Medicare Extra Help, and International Pharmacies instead.

* How we calculated the savings estimate: The lower bound ($500/year) reflects average annual savings for patients using GoodRx discount cards on common generic medications, based on GoodRx's published data showing an average 82% savings off retail prices across ~25 million users (GoodRx, 2024). The upper bound ($3,000/year) reflects savings for patients on expensive brand-name cardiac medications (e.g., Xarelto 20mg or Eliquis 5mg) who switch from US retail pricing (~$500–$550/month) to verified international pharmacies (~$80–$130/month) via PharmacyChecker-accredited sources — a difference of approximately $1,500–$4,600/year. Patient Assistance Programs (PAPs) can yield even greater savings for eligible patients; a peer-reviewed study (PMC, 2022) found PAPs saved patients an average of $3,072/year at a single cancer center. Savings vary significantly by medication, insurance status, and program eligibility. These figures are illustrative estimates, not guarantees. GoodRx Impact Report · PharmacyChecker · PMC PAP Savings Study (2022)